Biotech is my comfort zone. I am a risk-taking investor looking for big gains. I'm already up over 30% here and I believe I'm still early here, but certainly not as tenured as many of you.
If retail is not an effort to attract financing, what might be a better audience. The CVS brand name is a shout of legitimacy to the naysayer. I think it's critical to the next stages of this company.
I am aware of the remaining products that are geared more towards compliance and big pharmaceutical companies as a potential co-opt of safe dosing. But do you think the pharmaceutical company will finance RXSF for a royalty, or just buy her out?
News 
Market Data 
Discover 
